| DNAJC17 | |
|---|---|
| Gene Symbol | DNAJC17 |
| Full Name | DnaJ Heat Shock Protein Family Member C17 |
| Chromosomal Location | 15q21.1 |
| NCBI Gene ID | 56126 |
| Ensembl ID | ENSG00000149691 |
| OMIM ID | 613358 |
| UniProt ID | Q9NWV8 |
| Protein Length | 304 amino acids |
| Molecular Weight | 34.5 kDa |
DNAJC17 (DnaJ Heat Shock Protein Family Member C17) is a member of the DNAJ family of co-chaperones, which are characterized by the presence of a conserved J domain that enables them to interact with Hsp70 heat shock proteins and regulate their ATPase activity. DNAJC17 is a Type II DNAJ protein, containing a J domain at the N-terminus followed by a glycine/phenylalanine-rich region and a C-terminal client-binding domain. While DNAJC17 was initially predicted to function as a molecular chaperone, its exact biological roles and disease associations remain an active area of investigation.
The DNAJ protein family (also known as Hsp40 family) consists of over 40 members in humans, categorized into three main classes based on their domain architecture: Type I (DNAJA), Type II (DNAJB), and Type III (DNAJC). DNAJC17 represents a relatively uncharacterized member of this family, with emerging evidence suggesting roles in protein quality control, RNA processing, and potentially in neurodegenerative disease contexts.
The DNAJC17 gene is located on chromosome 15q21.1, spanning approximately 8.5 kilobases of genomic DNA. The gene consists of 9 exons encoding a 304-amino acid protein. The gene structure is relatively simple compared to other DNAJ family members, with a compact architecture reflecting its specialized function.
DNAJC17 exhibits broad but specific expression patterns across human tissues:
Within the central nervous system, DNAJC17 expression has been detected in multiple brain regions, including the cerebral cortex, hippocampus, cerebellum, and hypothalamus. The neuronal expression suggests potential roles in brain function and neurological disease.
DNAJC17 localizes primarily to the cytoplasm, where it can interact with its Hsp70 partners. Some studies suggest additional localization to the nucleus, particularly in association with RNA processing compartments. The protein may also associate with mitochondria in certain cell types.
DNAJC17 contains several functional domains:
J Domain (aa 35-97): The signature domain of DNAJ proteins, containing the HPD motif (Histidine-Proline-Aspartate) critical for Hsp70 interaction. This domain stimulates Hsp70 ATPase activity.
Glycine/Fenylalanine-Rich Region (aa 98-150): A flexible linker region with potential client protein interaction sites.
C-terminal Client-Binding Domain (aa 151-304): Mediates interaction with unfolded or misfolded protein substrates.
While DNAJC17 remains incompletely characterized, several molecular functions have been proposed:
Chaperone Activity: As a DNAJ co-chaperone, DNAJC17 likely assists Hsp70 in protein folding, refolding, and clearance of misfolded proteins. The J domain couples substrate delivery to Hsp70 ATP hydrolysis.
Protein Quality Control: DNAJC17 may participate in the cellular protein quality control network, helping to target damaged or aggregation-prone proteins for refolding or degradation via the proteasome or autophagy pathways.
RNA Processing: Some evidence suggests DNAJ proteins can associate with RNA-protein complexes, potentially linking protein quality control to RNA metabolism.
While direct evidence linking DNAJC17 to Alzheimer's disease (AD) is limited, several indirect connections suggest potential involvement:
Protein homeostasis disruption: AD is characterized by accumulation of misfolded proteins (amyloid-beta, tau). DNAJC17 may help manage proteotoxic stress, and alterations in its expression could affect disease progression.
Hsp70 involvement: Hsp70 and its co-chaperones are major players in protein aggregation management. Modulating DNAJC17 levels could influence Hsp70 activity in AD brain.
Transcriptional regulation: Some DNAJ proteins regulate gene expression, potentially affecting pathways relevant to neurodegeneration.
Similar considerations apply to Parkinson's disease (PD):
Alpha-synuclein handling: The aggregation of alpha-synuclein is central to PD pathogenesis. DNAJC17 may contribute to managing synuclein proteostasis.
Mitochondrial quality control: PD involves mitochondrial dysfunction. DNAJ proteins participate in mitochondrial protein import and quality control.
ALS involves aggregation of TDP-43, FUS, and SOD1 proteins. DNAJ proteins may influence the handling of these disease proteins.
DNAJC17 primarily interacts with cytosolic Hsp70 proteins:
While specific client proteins for DNAJC17 are not well established, the protein may handle:
DNAJC17 participates in several cellular pathways:
While DNAJC17 is not currently a therapeutic target, understanding its function may provide insights into:
Modulating protein quality control: Enhancing DNAJC17 function could improve clearance of misfolded proteins in neurodegeneration.
Combination therapies: Targeting multiple DNAJ proteins may have additive benefits.
Biomarkers: DNAJC17 expression could serve as a marker of cellular proteostasis capacity.
DNAJC17 is a member of the DNAJ/Hsp40 co-chaperone family with predicted roles in protein quality control and potentially in RNA processing. While its exact functions remain under investigation, DNAJC17 participates in Hsp70-mediated protein folding and clearance pathways relevant to neurodegenerative diseases. Further research is needed to fully characterize DNAJC17's biological roles and therapeutic potential in conditions like Alzheimer's, Parkinson's, and ALS.